• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

Low-dose pemetrexed need to be administered cautiously in patients with renal insufficiency

May 8, 2020
-
News
-
Posted by admin
kidneys

With acceptable rates of toxicity, pemetrexed monotherapy with reduced doses might be a safe treatment among patients with renal insufficiency.

A study published in the Journal of Oncology Pharmacy Practice conducted this dose depended on the safety analysis of pemetrexed. Pemetrexed is an effective and well-tolerated drug for lung cancer. However, in patients with a creatinine clearance (CrCl) < 45 ml/min, this drug is not recommended due to increased cases of myelosuppression, who otherwise could be declared fit for the treatment.

In case of organ dysfunction, many drugs are used in a dose adjusted manner to match the safety standards. However, there was no similar study done attributed to pemetrexed so far.

This analysis opens the new doors of pemetrexed for patients with renal insufficiency. The research was conducted by Jordan Hill and colleagues at the James Cancer Hospital and Solove Research Institute at the Ohio State University.

It was a retrospective case series that involved a total of eighteen patients who obtained a minimum one dose of pemetrexed. On day 1 of each 21-day cycle of treatment, the drug was administrated as 10 minutes intravenous infusion. In treatment, the number of cycles was decided according to the treatment goal and tolerability. During the course, the drug was co-administrated with folic acid, dexamethasone and cyanocobalamin as per scheduled treatment. The measurement of toxicity was done using CTACE version 4.0. It is the common terminology criteria for adverse events.

As per the outcomes, the single-agent dose-adjusted pemetrexed can be given cautiously among patients with CrCl between 30 and 45 ml/min. However, pemetrexed as concomitant chemotherapy with platinum is not recommended among patients with CrCl < 30 ml/min. Even for 20% preemptive dose reduction an extra caution is needed for concomitant therapy because of high risk of grade ≥ 3 hematologic toxicity. Further reduction was not assessed among these patients. A further research analysis may be required.

Reference

Tags
ADMAC Oncology
Lung cancer treatment
Pemetrexed
← PREVIOUS POST
Subcutaneous bortezomib has become the standard of care in multiple myeloma

Related News

Other posts that you should not miss.
anti-cancer-food-admac

Super anti-cancer foods you need to know

August 29, 2020
-
News

The disease management pays considerable attention to dispensing effective health modalities, resulting in a significant decrease in disability and mortality but at the expense of high and traumatic …

Read More →
Posted by seoaccount medivisual
6 MIN READ
Gemtuzumab-ozogamicin-admac

Gemtuzumab ozogamicin receives FDA-approval for CD33-positive acute myeloid leukemia in pediatrics

August 10, 2020
-
News

For newly diagnosed CD33-positive AML (acute myeloid leukemia), the FDA (Food and Drug Administration) extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) on 16 June 2020 …

Read More →
Posted by seoaccount medivisual
1 MIN READ
breast-cancer-preventive-tips-admac

Breast cancer: Effective cancer preventive tips to consider

October 31, 2020
-
News

Breast cancer incidences are rising in the developing world. It is the most common type of cancer that occurs in women.  Most forms of this cancer are invasive. …

Read More →
Posted by seoaccount medivisual
4 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
Pemetrexed - A Drug For Lung Cancer | Know More | Admac